cyrilzakka/clinical-trials huggingface dataset:
Effectiveness of Diclofenac and Its Association to Codeine After Lower Third Molar Extraction.

It will be evaluated the clinical efficacy of Diclofenac 50mg (NSAID) compared to its association with Codeine 50mg (opioid) administered in 50 patients requiring extraction of two third molars. After assessing the research parameters, a comparative data analysis, along with the proper application of statistical tests, will provide the basis for an evaluation of both efficiency medications used.

This research will evaluate the clinical efficacy of Diclofenac 50mg (NSAID) compared to its association with Codeine 50mg (opioid) administered in 50 patients aged less than 18 and requiring extraction of two third molars (with very similar positions, whose degree of difficulty is high). It will be assessed the following parameters: 1) onset and duration of surgery after administration of local anesthetic, 2) open mouth prior to surgery, on the 2nd day after the operation and on the 7th day after surgery (removal points), 3) subjective assessment of pain using a visual analog scale, 4) measurement of facial edema in the second day after the operation and on the 7th day after surgery (as compared with the measurements obtained before surgery) and 5) the incidence, type and severity of adverse reactions. The analysis comparative data, along with the proper application of statistical tests, provide the basis for an evaluation of both efficiency medications used.

Eligibility Criteria:
Inclusion Criteria:

* Impacted lower third molar
* not in use of NSAID or opioids in the last one month

Exclusion Criteria:

* Local anesthetics allergy,
* History of gastrointestinal bleeding or ulcers,
* Kidney disease,
* Asthma,
* Allergy or sensitivity to aspirin or any other NSAID or opioids,
* Pregnant or nursing woman,
* Patients using antidepressant, diuretic or aspirin,
* Patients under treatment to quit drugs
Cardiac Output Monitoring by Transpulmonary Thermodilution and Transthoracic Echocardiography in Critically Ill Patients

Cardiac output monitoring is a key component for the diagnosis and management of critically ill patients. The two less invasive methods commonly used in intensive care are transthoracic echocardiography and transpulmonary thermodilution. The objective of this study is to compare accuracy and trending ability of CO measurement by TPTD and TTE in critically ill patients with sinus rhythm.

TTE is an easy noninvasive device now recommended as the first evaluation of the patient in circulatory failure but it present some limits due to poor echogenicity of patients, operator-dependent variability and cannot provide continuous hemodynamic data. TPTD is an invasive technique for CO monitoring recommended especially in shock not responsive to initial therapy.

Few studies have evaluated the level of agreement of each method (TTE and TPTD) with the reference method (pulmonary artery catheter) but they have never been compared between them with strong statistical analysis in particular trending ability.

It could be interesting to determine the level of concordance of these two methods of CO monitoring and trend ability by TPTD relative to TTE.

The investigators hypothesize that CO-TPTD are concordant with those performed by TTE.

Mechanically ventilated patients requiring hemodynamic assessment will be included. CO-TPTD will be measured via intermittent thermodilution. Blindly, a second investigator will use standard-view TTE to estimate CO-TTE as the product of stroke volume and the heart rate obtained during the measurement the blood flow velocity (using a Doppler technique) at the left ventricular outflow tract. A second measurement will be done with the two devices after a fluid challenge when patient requires it to compare trending ability.

Eligibility Criteria:
Inclusion Criteria:

* mechanically ventilated and sedated patients
* with sinus rhythm
* hospitalized in Intensive Care Unit
* fitted with an hemodynamic monitoring by thermodilution technique due to hemodynamic failure

Exclusion Criteria:

* age under 18
* arrhythmia
* severe aortic regurgitation or stenosis
* intracardiac shunt
* poor echogenicity
* tamponade
* major subject to a legal protection regim.
Piperacillin/Tazobactam for Empirical Therapy of Febrile Neutropenia

Neutropenia is very common in patients received hematopoietic stem cell transplantation, with median duration of about 14 days. In 2010 update, IDSA recommended Piperacillin/tazobactam as first-line mono-therapy for febrile patients with neutropenia of high risk. In china, the data of piperacillin/tazobactam for febrile neutropenia after hematopoietic stem cell transplantation is very limited.

The current study will evaluate the efficacy of piperacillin/tazobactam compared with imipenem/cilastatin for febrile neutropenia after transplantation.

1. Swab culture (skin, pharyngeal, nasal, anus) when administered into laminar flow room after transplantation.
2. Randomize the febrile patients into 2 groups.
3. Therapy group receive piperacillin/tazobactam, 4.5g q6h iv. Control group receive imipenem/cilastatin, 0.5g q6h. Duration will be 5-10 days.

Eligibility Criteria:
Inclusion Criteria:

* Age 13-65 years
* received Autologous or Allogeneic hematopoietic stem cell transplantation.
* ECOG score 0-1.
* ICF is available.

Exclusion Criteria:

* Allergic to any therapy drug.
* Documented infection before neutropenia.
* Renal dysfunction.
* Suffering from central nervous system or mental disease.
Validation of Gene Expression Markers of Renal Allograft Functional Decline

The purpose of this study is to determine if certain genes found in a kidney biopsy performed at one-year post transplant can predict which transplanted kidneys will have decreased kidney function within five years post-transplant.

Gene expression profiling is used to study the activity of genes. Each gene has an "on/off" switch that controls how they are expressed in a cell, as well as a "volume control" that increases or decreases the level of expression of a particular gene as necessary. Researchers want to see if the presence and abundance of certain transcripts in a kidney biopsy at one year after transplant can predict which kidneys will have reduced function over time.

Eligibility Criteria:
Inclusion Criteria:

* Adult (≥18 years) conventional renal transplant recipient.
* Patients who have given informed consent and are willing to comply with the protocol.

Exclusion Criteria:

* ABO incompatible kidney transplants.
* Positive crossmatch kidney transplants (T cell crossmatch \>100, B flow cytometric crossmatch \>150).
* Simultaneous kidney and extra-renal organ transplants including pancreas, liver, heart, lung, etc. Subjects who had previous extra renal transplants may be included in the study.
* Patients taking chronic anticoagulation, which includes Coumadin, Plavix and any type of heparin. Aspirin is acceptable but must be stopped 5 days prior to the renal biopsy.
* An inability to have the 1-year renal biopsy performed within the acceptable protocol window (Months 11-14 \[Days 301-420\] post-transplant).
Comparative Study of the Hemorrhagic Risk in Patients Over 75 Years of Age Taking Enoxaparin

Elderly subjects are at greater risk of thrombophlebitis than the general population, but also of bleeding when anticoagulant therapy is initiated.

Enoxaparin is one of the most widely used anticoagulants in the management of venous thromboembolism in the world.

Its use is not codified in the elderly, because too few studies have been carried out in people over 75 years old.

For several years, Enoxaparin in curative treatment has been administered at a reduced dosage of 4000 IU twice a day (and not at a standard dose of 100 IU / kg) at the Geriatrics center of the CRHU in Strasbourg with the clinical impression of a reduction the risk of serious bleeding without reduction in therapeutic efficacy in this very elderly population.

Confirmation of a reduction in the risk of bleeding at this dosage could be the start of a change in prescribing practices, towards a more suitable dosage in the elderly.


Eligibility Criteria:
Inclusion criteria:

* Subjects of age\> = 75 years
* Having a weight\> = 45kg for women and\> = 57kg for men and a BMI \<30, a GFR\> 30 ml / min in Cockcroft-Gault, and having benefited from treatment with Enoxaparin for deep vein thrombosis and / or pulmonary embolism between 01/01/2000 to 11/30/2021.
* Subject having been informed by posting in the service and / or via the welcome booklet and not having expressed his opposition to the reuse of his data.

Exclusion criteria:

* Subject having expressed opposition to participating in the study
* History of heparin-induced thrombocytopenia in the last 100 days,
* condition associated with a high risk of bleeding such as congenital or acquired blood pathology,
* a recent hemorrhagic stroke,
* a gastrointestinal ulcer,
* the presence of a malignant tumor at high risk of bleeding, recent surgery of the brain, spine or ophthalmology, known or suspected oesophageal varices, arteriovenous malformations, a vascular aneurysm or major intraspinal or intracerebral vascular anomalies.
Renal Denervation Hypertension After Stroke

It is known, that hypertension is the major risk factor of stroke and recurrent stroke. Blood pressure reduction - together with antithrombotics - remain crucial in stroke prevention.

This pilot study will examine the effect of renal nerve denervation in patients with treatment resistant hypertension after ischemic stroke or DWI/DTI-verified stroke. With 24 hours blood pressure measurements the effect after renal nerve denervation is examined 1,3,6 and 12 months after the procedure.

Radio frequent ablation is used to renal nerve denervation (RND) and is a new invasive method used in treatment for hypertensive patients, where the sympathetic nerves to the kidneys ablates. RND shows a significant reduction in the systolic and diastolic blood pressure in patients with treatment resistant hypertension.

The hypothesis is that RDN is able to reduce the blood pressure in patients with previous stroke and treatment resistant hypertension and thereby reduce the risk of a new stroke.

Aim of study:

1. To validate the reduction in blood pressure after RND in patients with stroke and treatment resistant hypertension compared to the results achieved in patients only with essential hypertension
2. To examine if this treatment is possible on patients after stroke (procedure related limitations and security of the patient)
3. To describe the effect of RND in the development of changes in the white matter over time

Eligibility Criteria:
Inclusion Criteria:

* 18+ years old
* Clinical verified stroke within the last year
* Treatment resistant hypertension at 150 mm Hg or higher systolic at consultation
* Modified Ranking between 0-2

Exclusion Criteria:

* Lack of informed consent
* Renal artery anatomy, which prevents the procedure
* Reno vascular disease
* Pacemaker
* Haemodynamic vascular occlusion or valve disease
* Pregnancy or women in the childbearing age
* Secondary hypertension
* Mean systolic blood pressure over 180 mm Hg
Tenofovir Monotherapy in Patients With Chronic Hepatitis B Patients Who Had Achieved Complete Viral Suppression on Entecavir Plus Tenofovir

Little is known about efficacy of switching to tenofovir monotherapy for multidrug-resistant chronic ehpatitis B patients who achieved a complete virological response to entecavir and tenofovir. This study aimed to investigate the efficacy of switching to tenofovir monotherapy for multidrug-resistant chronic hepatitis B patients with undetectable heaptitis B virus DNA while on tenofovir plus entecavir combination therapy.


Eligibility Criteria:
Inclusion Criteria:

* HBsAg (+) for \> 6 months age \>19 years antiviral resistance to LAM(rtL180M and/or M204V/I) \& ADV (rtA181V/T and/or rtN236T) or ETV (rtT184A/C/F/G/I/L/S, rtS202G, or rtM250L/V, in addition to rtM204V/I) HBV DNA levels \<20 IU/ml on two consecutive tests of 3-month interval currently receiving TDF+ETV for more than 12 months

Exclusion Criteria:

* Cr ≥1.5 mg/dL Evidence of decompensated liver disease Malignant neoplasm Coinfection with HIV, HCV
Respiratory Functions in Pediatric-Onset Multiple Sclerosis

Pediatric-onset multiple sclerosis (POMS) is a chronic, autoimmune and inflammatory disease of the central nervous system that begins before the age of 18 years. POMS patients are affected in terms of physical capacity, cognitive status and fatigue compared with their healthy peers that has been reported. It has been reported that although individuals with MS with low disability levels do not have respiratory complaints, respiratory parameters may be affected. Therefore, it is necessary to evaluate respiratory capacity, respiratory muscle strength and fatigue levels of POMS patients. Evaluations will help prevent future complications by detecting any existing problems early.

People with pediatric onset multiple sclerosis (POMS) may experience sensory, motor, cerebellar and cognitive dysfunctions due to the destruction of the central nervous system. These disorders can cause decrease in physical capacity, increase in cognitive symptoms and fatigue level in patients with POMS. There is no study in the literature examining the relationship between respiratory capacity and respiratory muscle strength with fatigue in POMS patients. The aim of this study is to compare POMS patients and healthy controls in terms of respiratory capacity, respiratory muscle strength and fatigue. All participants's respiratory function will be evaluated with "Minispir Light Spirometer", respiratory muscle strength with "MD Diagnostics RP Check" and fatigue with Pediatric Quality of Life Inventory (PedsQL)-Multidimensional Fatigue Scale. Evaluations will not be repeated after a certain interval.As a result of the comparison of both groups, it will be determined whether POMS patients have difficulties or not.

Eligibility Criteria:
Inclusion Criteria:

* Volunteer to participate
* Being diagnosed with pediatric onset multiple sclerosis
* Being between the ages of 15-22
* EDSS \<6

Exclusion Criteria:

* Having another diagnosis in addition to the diagnosis of pediatric-onset multiple sclerosis
* Having a blurred vision problem
* Having had an attack or received corticosteroid treatment 3 months before participating in the study
Distal Protection Device in ST-elevation Myocardial Infarction (STEMI)

The investigators examined the mechanism underlying the lack of benefit from distal protection and thrombus aspiration (DP-TA) in 126 patients with ST-elevation Myocardial Infarction (STEMI) in a prospective, randomized trial.

Patients with first-diagnosed STEMI were randomly assigned to distal protection and thrombus aspiration (DP-TA) pretreatment during percutaneous coronary intervention (PCI) or conventional PCI (c-PCI).

The primary endpoint was the remodeling index (RI), measured by cardiac magnetic resonance imaging (CMR) post-PCI and 6 months after PCI.

Secondary endpoints, determined by CMR within 3 to 5 days after PCI, included the infarct ratio (infarct size to entire left ventricular \[LV\] size ) by delayed-enhancement (DE), area at risk (AAR) ratio (AAR to LV size) by T2 high-signal intensity , microvascular occlusion index (MVO) ratio (MVO to LV size) by DE, and myocardial salvage index (MSI, \[AAR-infarct size\] x 100/AAR).

Eligibility Criteria:
Inclusion Criteria:

* 30 and less than 80 years presenting with STEMI
* more than 30 minutes but less than 12 hours after symptom onset
* with ≥ 2 mm of ST-segment elevation in 2 or more contiguous leads or with a presumably new left bundle-branch block
* for whom primary PCI was intended

Exclusion Criteria:

* included thrombolytic therapy before PCI;
* spontaneous restoration of coronary flow (\> TIMI grade II or III);
* cardiogenic shock (Killip class IV);
* major surgery or active bleeding within 6 weeks;
* aspirin, thienopyridine, or heparin allergy;
* neutropenia (\<1000 neutrophils/mm3), thrombocytopenia (\<100000 platelets/mm3), hepatic dysfunction, or renal insufficiency (serum creatinine level \>2.5 mg/dL \[221 μmol/L\]);
* noncardiac condition with expected survival less than 1 year;
* current participation in other investigations.
Impact of Intravitreal Aflibercept Injections on Capillary Non-Perfusion

The purpose of this study is to look at how effective, safe, and well tolerated Intravitreal Aflibercept Injection is in subjects with Central Retinal Vein Occlusion (CRVO) or Proliferative Diabetic Retinopathy (PDR).

Protocol available upon request.

Eligibility Criteria:
Inclusion Criteria:

1. Diagnosis of one or more of the following:

   Proliferative retinopathy (PDR) Macular edema secondary to CRVO Proliferative disease secondary to CRVO (anterior segment or posterior segment neovascularization).
2. Be in need of IAI treatment, whether previously treated or treatment-naïve.
3. Age \> 18 years.

Exclusion Criteria:

1. Subjects with macular edema secondary to diabetic retinopathy without concomitant proliferative diabetic retinopathy.
2. Subjects with cataract or other media opacities impairing adequate visualization of the retina to the extent that good quality images are impossible.
3. Presence of any substantial ocular disease (other than diabetic retinopathy or central retinal vein occlusion) that may compromise vision in the study eye and /or confound interpretation of the data; e.g. substantial cataracts, advanced glaucoma, optic neuritis, optic neuropathy or atrophy, marked macular atrophy, history of retinal detachment, uveitis, viral or other forms of chorioretinitis, etc.
4. Active intraocular inflammation (grade trace or above) in the study eye, or history of idiopathic or autoimmune-associated uveitis in either eye.
5. Uncontrolled glaucoma in the study eye (defined as intraocular pressure ≥ 25 mmHg despite treatment with anti-glaucoma medication).
6. History of rhegmatogenous retinal detachment or macular hole (Stage 3 or 4) in the study eye.
7. Participation in a study of an investigational drug or device within 30 days prior to potential enrollment into the study.
8. Intraocular surgery (including cataract surgery) in the study eye within 60 days preceding baseline.
9. History of vitrectomy surgery in the study eye.
10. Subjects with 12 or more anti-VEGF injections within 24 months prior to Screening.
11. Subjects who received anti-VEGF therapy within 30 days of Screening or received steroid or laser therapy within 90 days of Screening.
12. Subjects allergic to fluorescein, povidone iodine (Betadyne) or aflibercept
13. Pregnant or breast-feeding women.
Molecular Profiling and Dynamic Changes of ctDNA in Unresectable Locally Advanced NSCLC

Multi-center observational clinical study to evaluate the application value of ctDNA monitoring in efficacy assessment and relapse prediction in patients diagnosed with unresectable, locally advanced NSCLC receiving CRT with or without durvalumab maintenance treatment.

Newly diagnosed, histologically confirmed, unresectable stage III NSCLC patients, amenable to receive standard of care chemoradiotherapy with or without durvalumab maintenance, will be enrolled in this study. Whole blood collection will be conducted during the treatment for ctDNA detection in specific time-points of interest. Next-generation sequencing using commercially available panels, and analysis of ctDNA aberrant methylation will be performed. Results will be correlated to patients' recurrence times and survival outcomes.

Eligibility Criteria:
Inclusion Criteria:

* Patients with newly diagnosed, histologically confirmed, unresectable locally advanced NSCLC.
* ≥18 years of age.
* Ability to understand the written informed consent and willingness to sign it.

Exclusion Criteria:

* Patients who are unwilling to follow-up evaluation of response to therapy.
* Any condition that, in the opinion of the investigator, would interfere with study results.
Balance, Cognıtıve Skılls, Hand Functıons and Qualıty of Lıfe Among Patients with Bronchiectasis and Healthy Peers

The aim of this study is to comparatively evaluate the parameters of balance, cognitive skills, hand grip strength, reaction time, quality of life and respiratory functions in elderly and healthy peers individuals.

Deterioration of airway patency, respiratory functions, experiencing shortness of breath that limits functional capacity, impairments in health-related quality of life, balance, cognitive skills, hand grip strength and reaction time parameters make physiotherapy approaches important in the treatment of bronchiectasis.

Eligibility Criteria:
Inclusion Criteria:

* Clinically diagnosed with bronchiectasis and in stable condition,
* No known systemic, orthopedic or neurological disease,
* Can walk,
* Volunteer for research,
* Able to cooperate,
* Elderly individuals aged 65 and over with bronchiectasis
* Healthy elderly individuals aged 65 and over

Exclusion Criteria:

* Individuals under 65 years of age
* Individuals with FEV1 values \< 40%
* History of uncontrolled hypertension, arrhythmia and MI in the last month
* Having a history of lung or liver transplantation,
* Unstable angina,
* Those with serious cardiac problems such as advanced heart failure,
* Hemodynamically unstable cases,
* Those who have used antibiotics in the last three weeks,
* Those with acute exacerbation
* Those with insufficient awareness and cooperation,
* Those with pregnancy and malignancy,
* Those who have orthopedic or surgical problems that may prevent tests,
* Those who did not agree to participate in the research
Genetic Studies in Liver Cancer Patients

Hepatocellular carcinoma (HCC) is one the most common malignancies in the world, especially in sub-Saharan Africa and Southeast Asia. Since 1984, it has been the leading cause of cancer death in Taiwan. About 6000-8000 people died of this cancer every year in Taiwan. DNA microarray (DNA chip) is a very powerful tool to clarify the genetic changes in cancers. Expression profiling techniques have been used to simultaneously monitor the expression of thousands of genes from human tumor samples. It has been successfully used to predict clinical outcome and survival as well as classify different types of cancer. In this study, we will use the DNA chip to study the genetics in liver cancer patients.

The clinical samples will be collected in the NTUH, while the DNA microarray works will be done in Biomedical Engineering Center (BMEC) of ITRI.

Patients A total of 40 cases of HCC patients (20 HBV-related HCC and 20 HCV-related HCC) who received surgical resection in National Taiwan University Hospital will be enrolled from our tissue banks. The diagnosis of HCC was confirmed by pathological examination. The surgical specimens were frozen immediately after surgery and stored in -140°C. The clinicopathological data will be retrospectively obtained from chart reviews.

Another total of 40 new HCC patients who receive surgical resection in National Taiwan University Hospital will be collected. The healthy subjects and patients chronically infected with HBV or HCV without HCC will be used as controls. The whole bloods will be collected before, one and six months after operation. The diagnosis of HCC will be confirmed by pathology. In addition to the whole bloods, the surgical specimens will be frozen immediately after surgery and stored in -140°C.

Eligibility Criteria:
Inclusion Criteria:

* hepatocellular carcinoma

Exclusion Criteria:

* multiple cancers